DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences
News provided by
Share this article
Share this article
MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April, 2021. Financial terms of this transaction have not been disclosed.

Related Keywords

Kira Sheinerman ,Interpace Biosciences ,Interpace Bioscience ,Prnewswire Diami ,Interpace Biopharma ,Samuil Umansky ,Interpace Biosciences Inc ,Clinical Laboratory Improvement Amendments ,New Haven ,Chief Scientific Officer ,Diamir ,மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் ,புதியது புகலிடம் ,தலைமை அறிவியல் அதிகாரி ,